CLAIMS

What is claimed is:

Compounds having the Formula I 1.

wherein:

Ra, Rb, Rc are each independently C1-C6 alkyl or hydrogen;

 R^d , R^e , R^f , and R^g are each independently $C_1\text{-}C_6$ alkyl, hydrogen, or phenyl;

$$^{\mid}$$
 $^{\mid}$ $^{\mid}$

$$---(CH2)n---phenyl,$$

$$--(CH_2)_n$$

$$---(CH2)n ----C1-C6 alkyl ,$$

$$-(CH_2)_n$$
 —heteroaryl, or


$$--$$
(CH₂)_n $--$ substituted phenyl;

10

5

5

10



R⁴ is aryl, substituted aryl, or C₁-C₆ alkyl; and each n is independently 0 to 5, m is 2 to 4 and the pharmaceutically acceptable salts, and prodrugs thereof.

- A compound according to Claim 1 wherein
 Y is -O-.
- 4. A compound according to Claim 1 wherein R^a is hydrogen, R^b is methyl, and R^c is hydrogen.
- 5. A compound according to Claim 1 wherein

15
$$R^3$$
 is $-(CH_2)_n$ O-benzyl

6. A compound according to Claim 1 wherein R³

10


15

A compound according to Claim 1 wherein
R² is

-CH₂CH₂- phenyl or -CH₂CH₂-substituted phenyl.

8. A compound according to Claim 1 wherein

5 R^2 is



9. A compound according to Claim 1 wherein

 R^2 is


$$\begin{array}{c|c} H \\ \hline \begin{array}{c} I \\ C \\ \hline \end{array} \\ \begin{array}{c} C \\ \end{array} \\ \\ \begin{array}{c} C \\ \end{array} \\ \begin{array}{c} C \\$$

20 10. A compound according to Claim 9 wherein m of

$$\begin{array}{c|c} H & H \\ \hline \begin{array}{c} C \\ C \\ \end{array} \\ \begin{array}{c} C \\$$

m is 3 or 4.

11. A compound according to Claim 1 wherein R³ is -(CH₂)_n-C₁-C₆ alkyl.



$$R^3$$
 is $---(CH_2)$ $-- OCH_2$ -pyridyl .

13. The compounds:

 $[S-(R^*,R^*)]-[1-\{[2-(4-Benzyloxy-phenyl)-1-phenethyl-carbamoyl-ethyl]-methyl-carbamoyl\}-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[1-\{[2-(4-Benzyloxy-phenyl)-1-(2-methyl-2-phenyl-propylcarbamoyl)-ethyl]-methyl-carbamoyl\}-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[2-(1H-Imidazol-4-yl)-1-(methyl-\{1-(2-methyl-2-phenyl-propylcarbamoyl)-2-[4-(pyridin-2-ylmethoxy)-phenyl]-ethyl\}-carbamoyl)-ethyl]-carbamic acid benzyl ester;$

[S-(R*,R*)]-2-(3-Benzyl-3-methyl-ureido)-N-[2-(4-benzyloxy-phenyl)-1-(2-methyl-2-phenyl-propyl-carbamoyl)-ethyl]-3-(1H-imidazol-4-yl)-N-methyl-propionamide;

 $[S-(R^*,R^*)]-[1-\{[2-(4-Benzyloxy-phenyl)-1-[(1-phenyl-cyclobutylmethyl)-carbamoyl]-ethyl\}-methyl-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[2-(3H-Imidazol-4-yl)-1-\{methyl-[1-(2-methyl-2-phenyl-propylcarbamoyl)-2-phenyl-ethyl]-carbamoyl\}-ethyl-carbamic acid benzyl ester; and$

 $[S-(R^*,R^*)]-[2-(3H-Imidazol-4-yl)-1-\{methyl-[3-methyl-1-(2-methyl-2-phenyl-propylcarbamoyl)-butyl]-carbamoyl\}-ethyl-carbamic acid benzyl ester.$

14. The compounds:

10

5

15

20



 $[S-(R^*,R^*)]-[1-(\{2-(4-Benzyloxy-phenyl)-1-[2-(2-fluoro-phenyl)-ethyl-carbamoyl]-ethyl\}-methyl-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[1-\{[2-(4-Benzyloxy-phenyl)-1-(2-pyridin-2-yl-ethyl-carbamoyl)-ethyl]-methyl-carbamoyl\}-2-(3 H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

[S-(R*,R*)]-[1-{[2-(4-Benzyloxy-phenyl)-1-(2,2-diphenyl-ethylcarbamoyl)-ethyl]-methyl-carbamoyl}-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;

 $[S-(R^*,R^*)]-[1-\{[2-(4-Benzyloxy-phenyl)-1-(2-phenyl-propylcarba moyl)-ethyl]-methyl-carbamoyl\}-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-(2-(3H-Imidazol-4-yl)-1-\{methyl-[3-methyl-1-(2-methyl-2-phenyl-propylcarbamoyl)-butyl]-carbamoyl\}-ethyl)-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[1-\{[2-(4-Benzyloxy-phenyl)-1-(1-methyl-2-phenyl-ethylcarbamoyl)-ethyl]-methyl-carbamoyl\}-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[1-(\{2-(4-Benzyloxy-phenyl)-1-[(1-phenyl-cyclopropyl-methyl)-carbamoyl]-ethyl}-methyl-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-[1-\{[2-(4-Chloro-phenyl)-1-(2-methyl-2-phenyl-propylcarbamoyl)-ethyl]-methyl-carbamoyl\}-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-2-(3-Benzyl-ureido)-3-(3H-imidazol-4-yl)-N-methyl-N-{1-(2-methyl-propyl-carbamoyl)-2-[4-(pyridin-4-ylmethoxy)-phenyl]-ethyl}-propionamide;$

[S-(R*,R*)]-[1-{[2-(4-Benzyloxy-phenyl)-1-(1-methyl-2-phenyl-ethylcarbamoyl)-ethyl]-methyl-carbamoyl}-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester;


10

5

15

20

25



 $[S-(R^*,R^*)]-(2-(3H-Imidazol-4-yl)-1-\{[2-(4-methoxy-phenyl)-1-(2-methyl-2-phenyl-propylcarbamoyl)-ethyl]-methyl-carbamoyl\}-ethyl)-carbamic acid benzyl ester;$

 $[S-(R^*,R^*)]-2-(3-Benzyl-ureido)-3-(3H-imidazol-4-yl)-N-methyl-N-[1-(2-methyl-2-phenyl-propylcarbamoyl)-2-phenyl-ethyl]-propionamide; and$

[S-(R*,R*)]-[1-[(2-(4-Benzyloxy-phenyl)-1-{[1-(2-fluoro-phenyl)-cyclopropylmethyl]-carbamoyl}ethyl)-methyl-carbamoyl]-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester.

- 15. A method of treating cancer, the method comprising administering to a patient having cancer a therapeutically effective amount of a compound of Claim 1.
- 16. A method of treating or preventing restenosis, the method comprising administering to a patient having restenosis or at risk of having restenosis a therapeutically effective amount of a compound of Claim 1.
- 17. A method of treating atherosclerosis, the method comprising administering to a patient having atherosclerosis a therapeutically effective amount of a compound of Claim 1.
- 18. A method of treating psoriasis, the method comprising administering to a patient having psoriasis a therapeutically effective amount of a compound of Claim 1.
- 19. A pharmaceutical composition that comprises a compound of Claim 1.



10

5

15

20